Last update: July 6, 2018
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Quinapril Hydrochloride in other languages or writings:
Quinapril Hydrochloride belongs to this group or family:
Main tradenames from several countries containing Quinapril Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 60 | % |
Molecular weight | 475 | daltons |
Protein Binding | 97 | % |
pKa | 3,7 | - |
Tmax | 2 | hours |
T1/2 | 3 | hours |
M/P ratio | 0,12 | - |
Relative Dose | 1,6 | % |
Write to us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Quinapril, via its active metabolite, quinaprilat, is an angiotensin converting enzyme inhibitor (ACEI) used in the treatment of high blood pressure and heart failure.
Oral administration every 12-24 hours.
It is excreted in breastmilk in clinically insignificant amounts (Anderson 2018, Begg 2001).
No problems have been observed in infants whose mothers were taking other ACEIs (Anderson 2018).
Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015).
The protective role of breastfeeding against maternal hypertension has been proven (Park 2018).